Trial Profile
A Phase 2 Interventional, Multicenter, Randomized Open Label Study to Determine the Effective and Tolerable Dose of KAF156 and Lumefantrine Solid Dispersion Formulation in Combination, Given Once Daily for 1, 2 and 3-days to Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2022
Price :
$35
*
At a glance
- Drugs Ganaplacide (Primary) ; Lumefantrine (Primary) ; Artemether/lumefantrine
- Indications Falciparum malaria
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Healthcare; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 23 Nov 2022 According to a Novartis media release, this trial receive funding from the European and Developing Countries Clinical Trials Partnership (EDCTP), which is supported by the European Union.
- 23 Nov 2022 Results presented in a Novartis Media Release.
- 05 Oct 2021 According to a Novartis media release, results from this study will be published in the New England Journal of Medicine.